Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410078, China (Luo P, Email: luoping1011@126. com).
Zhongguo Dang Dai Er Ke Za Zhi. 2021 Oct 15;23(10):1069-1074. doi: 10.7499/j.issn.1008-8830.2107153.
Systemic lupus erythematosus (SLE) is an autoimmune disease involving multiple organs, and lupus nephritis (LN) is the most common renal complication of SLE. Belimumab is a fully humanized monoclonal antibody that can reduce the number of B cells, thereby reducing the formation of autoantibodies. Belimumab can improve SLE response index and SLE disease activity score and delay the progression of LN in both adults and children and thus plays an important role in the treatment of SLE and LN. This article reviews related research reports of belimumab used in the treatment of children and adults with SLE in China and overseas and analyzes the efficacy and safety of belimumab in pediatric patients, in order to provide a reference for the clinical application of belimumab in children with SLE.
系统性红斑狼疮（SLE）是一种累及多器官的自身免疫性疾病，狼疮肾炎（LN）是 SLE 最常见的肾并发症。贝利尤单抗是一种完全人源化的单克隆抗体，可减少 B 细胞数量，从而减少自身抗体的形成。贝利尤单抗可改善 SLE 反应指数和 SLE 疾病活动评分，并延缓 LN 在成人和儿童中的进展，因此在 SLE 和 LN 的治疗中发挥着重要作用。本文综述了贝利尤单抗在中国和国外治疗儿童和成人 SLE 的相关研究报告，并对贝利尤单抗治疗儿科患者的疗效和安全性进行了分析，以期为贝利尤单抗在儿童 SLE 中的临床应用提供参考。
